Akoya Biosciences (Akoya Biosciences) Cash-to-Debt : 0.72 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Akoya Biosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.72.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Akoya Biosciences couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Akoya Biosciences's Cash-to-Debt or its related term are showing as below:

AKYA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: 1.07 Max: 4.12
Current: 0.72

During the past 5 years, Akoya Biosciences's highest Cash to Debt Ratio was 4.12. The lowest was 0.33. And the median was 1.07.

AKYA's Cash-to-Debt is ranked worse than
68.11% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: 1.89 vs AKYA: 0.72

Akoya Biosciences Cash-to-Debt Historical Data

The historical data trend for Akoya Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Akoya Biosciences Cash-to-Debt Chart

Akoya Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.88

0.49

3.43

1.07

0.97

Akoya Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													0.80	1.23	1.05	0.97	0.72

Competitive Comparison of Akoya Biosciences's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akoya Biosciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's Cash-to-Debt falls into.

Akoya Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Akoya Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	83.125	/	(3.448	+	82.258)
	=	0.97

Akoya Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	61.575	/	(3.372	+	81.816)
	=	0.72

Akoya Biosciences (NAS:AKYA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Akoya Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Akoya Biosciences (Akoya Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752

Website

https://www.akoyabio.com

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.

Executives

Brian Mckelligon	director, officer: President/CEO	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla	officer: Chief Operating Officer	C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler	director	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin	director, 10 percent owner	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler	director
Jennifer Kamocsay	officer: General Counsel	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll	officer: Chief Financial Officer	5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d.	director	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry	officer: Chief Medical Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy	officer: Chief People Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d	officer: Chief Business Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752